Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study.

Berardi R, Mastroianni C, Lo Russo G, Buosi R, Santini D, Montanino A, Carnaghi C, Tiseo M, Chiari R, Camerini A, Barni S, De Marino V, Ferrari D, Cristofano A, Doni L, Freddari F, Fumagalli D, Portalone L, Sarmiento R, Schinzari G, Sperandi F, Tucci M, Inno A, Ciuffreda L, Mariotti M, Mariani C, Caramanti M, Torniai M, Gallucci R, Bennati C, Bordi P, Buffoni L, Galeassi A, Ghidini M, Grossi E, Morabito A, Vincenzi B, Arvat E.

Ther Adv Med Oncol. 2019 Sep 27;11:1758835919877725. doi: 10.1177/1758835919877725. eCollection 2019.

2.

Adjuvant chemotherapy in resected bile duct cancer: A systematic review and meta-analysis of randomized trials.

Messina C, Merz V, Frisinghelli M, Trentin C, Grego E, Veccia A, Salati M, Messina M, Carnaghi C, Caffo O.

Crit Rev Oncol Hematol. 2019 Nov;143:124-129. doi: 10.1016/j.critrevonc.2019.09.002. Epub 2019 Sep 9.

PMID:
31563828
3.

Pancreatic Neuroendocrine Tumours: The Role of Endoscopic Ultrasound Biopsy in Diagnosis and Grading Based on the WHO 2017 Classification.

Di Leo M, Poliani L, Rahal D, Auriemma F, Anderloni A, Ridolfi C, Spaggiari P, Capretti G, Di Tommaso L, Preatoni P, Zerbi A, Carnaghi C, Lania A, Malesci A, Repici A, Carrara S.

Dig Dis. 2019;37(4):325-333. doi: 10.1159/000499172. Epub 2019 Mar 21.

PMID:
30897588
4.

The impact of cancer: An Italian descriptive study involving 500 long-term cancer survivors.

Muzzatti B, Gipponi K, Flaiban C, Cormio C, Carnaghi C, Tralongo P, Caruso M, Cavina R, Tirelli U, Annunziata MA.

Eur J Cancer Care (Engl). 2019 May;28(3):e13007. doi: 10.1111/ecc.13007. Epub 2019 Feb 10.

PMID:
30740807
5.

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.

Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F.

Gastroenterology. 2018 Aug;155(2):479-489.e7. doi: 10.1053/j.gastro.2018.04.010. Epub 2018 Apr 13.

PMID:
29655834
6.

Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?

Vigano L, Darwish SS, Rimassa L, Cimino M, Carnaghi C, Donadon M, Procopio F, Personeni N, Del Fabbro D, Santoro A, Torzilli G.

Ann Surg Oncol. 2018 Jun;25(6):1676-1685. doi: 10.1245/s10434-018-6387-8. Epub 2018 Feb 27.

PMID:
29488188
7.

Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases.

Viganò L, Pedicini V, Comito T, Carnaghi C, Costa G, Poretti D, Franzese C, Personeni N, Del Fabbro D, Rimassa L, Scorsetti M, Santoro A, Solbiati L, Torzilli G.

World J Surg. 2018 Aug;42(8):2651-2659. doi: 10.1007/s00268-018-4525-x.

PMID:
29423737
8.

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.

Rinzivillo M, Fazio N, Pusceddu S, Spallanzani A, Ibrahim T, Campana D, Marconcini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, Faggiano A, Antonuzzo L, Spada F, Gritti S, Femia D, Gelsomino F, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F.

Pancreatology. 2018 Mar;18(2):198-203. doi: 10.1016/j.pan.2018.01.005. Epub 2018 Jan 12.

PMID:
29361429
9.

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R.

Onco Targets Ther. 2017 Oct 16;10:5013-5030. doi: 10.2147/OTT.S142087. eCollection 2017.

10.

Long-term quality of life profile in oncology: a comparison between cancer survivors and the general population.

Annunziata MA, Muzzatti B, Flaiban C, Gipponi K, Carnaghi C, Tralongo P, Caruso M, Cavina R, Tirelli U.

Support Care Cancer. 2018 Feb;26(2):651-656. doi: 10.1007/s00520-017-3880-8. Epub 2017 Sep 16.

PMID:
28918552
11.

Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC.

Lancet Oncol. 2017 Oct;18(10):1411-1422. doi: 10.1016/S1470-2045(17)30471-0. Epub 2017 Aug 30.

PMID:
28838862
12.

Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM).

Salvatore L, Aprile G, Arnoldi E, Aschele C, Carnaghi C, Cosimelli M, Maiello E, Normanno N, Sciallero S, Valvo F, Beretta GD.

ESMO Open. 2017 Apr 12;2(1):e000147. doi: 10.1136/esmoopen-2016-000147. eCollection 2017. Review.

13.

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.

Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N; RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group.

Neuroendocrinology. 2018;106(3):211-220. doi: 10.1159/000477585. Epub 2017 May 24.

PMID:
28554173
14.

Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study.

Comito T, Cozzi L, Zerbi A, Franzese C, Clerici E, Tozzi A, Iftode C, Navarria P, D'Agostino G, Fogliata A, Mancosu P, Tomatis S, Carnaghi C, Personeni N, Santoro A, Scorsetti M.

Eur J Surg Oncol. 2017 Apr;43(4):735-742. doi: 10.1016/j.ejso.2016.12.012. Epub 2017 Jan 16.

PMID:
28131670
15.

Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study.

Comito T, Cozzi L, Clerici E, Franzese C, Tozzi A, Iftode C, Navarria P, D'Agostino G, Rimassa L, Carnaghi C, Personeni N, Tronconi MC, De Rose F, Franceschini D, Ascolese AM, Fogliata A, Tomatis S, Santoro A, Zerbi A, Scorsetti M.

Technol Cancer Res Treat. 2017 Jun;16(3):295-301. doi: 10.1177/1533034616650778. Epub 2016 Jun 16.

16.

Filamin-A is required to mediate SST2 effects in pancreatic neuroendocrine tumours.

Vitali E, Cambiaghi V, Zerbi A, Carnaghi C, Colombo P, Peverelli E, Spada A, Mantovani G, Lania AG.

Endocr Relat Cancer. 2016 Mar;23(3):181-90. doi: 10.1530/ERC-15-0358. Epub 2016 Jan 5.

PMID:
26733502
17.

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group.

Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.

18.

cAMP effects in neuroendocrine tumors: The role of Epac and PKA in cell proliferation and adhesion.

Vitali E, Cambiaghi V, Spada A, Tresoldi A, Zerbi A, Peverelli E, Carnaghi C, Mantovani G, Lania AG.

Exp Cell Res. 2015 Dec 10;339(2):241-51. doi: 10.1016/j.yexcr.2015.11.011. Epub 2015 Nov 14.

PMID:
26589262
19.

Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series.

Masci G, Caruso M, Caruso F, Salvini P, Carnaghi C, Giordano L, Miserocchi V, Losurdo A, Zuradelli M, Torrisi R, Di Tommaso L, Tinterri C, Testori A, Garcia-Etienne CA, Gatzemeier W, Santoro A.

Oncologist. 2015 Jun;20(6):586-92. doi: 10.1634/theoncologist.2014-0243. Epub 2015 May 6.

20.

FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.

Personeni N, Rimassa L, Verusio C, Barni S, Rubino L, Bozzarelli S, Villa E, Carnaghi C, Tronconi MC, Gerardi C, Galli F, Floriani I, Destro A, Raschioni C, Labianca R, Santoro A.

Clin Colorectal Cancer. 2015 Sep;14(3):162-9. doi: 10.1016/j.clcc.2015.02.006. Epub 2015 Mar 6.

PMID:
25861836
21.

MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.

Vaira V, Roncalli M, Carnaghi C, Faversani A, Maggioni M, Augello C, Rimassa L, Pressiani T, Spagnuolo G, Di Tommaso L, Fagiuoli S, Rota Caremoli E, Barberis M, Labianca R, Santoro A, Bosari S.

Liver Int. 2015 Mar;35(3):1077-86. doi: 10.1111/liv.12636. Epub 2014 Jul 21.

PMID:
25040368
22.

An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab.

Sclafani F, Rimassa L, Colombo P, Destro A, Stinco S, Lutman FR, Carnaghi C, Beretta G, Zanello A, Roncalli M, Giordano L, Santoro A.

Int J Biol Markers. 2015 Feb 24;30(1):e73-80. doi: 10.5301/jbm.5000097.

PMID:
24980447
23.

A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma.

Rimassa L, Pressiani T, Boni C, Carnaghi C, Rota Caremoli E, Fagiuoli S, Foa P, Salvagni S, Cortesi E, Chiara Tronconi M, Personeni N, Bozzarelli S, Chiara Banzi M, Fanello S, Romano Lutman F, Giordano L, Santoro A.

Oncologist. 2013;18(4):379-80. doi: 10.1634/theoncologist.2012-0221. Epub 2013 Apr 11.

24.

Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.

Personeni N, Rimassa L, Pressiani T, Destro A, Ligorio C, Tronconi MC, Bozzarelli S, Carnaghi C, Di Tommaso L, Giordano L, Roncalli M, Santoro A.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1179-87. doi: 10.1007/s00432-013-1429-x. Epub 2013 Apr 9.

PMID:
23568548
25.

Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey.

Cortinovis D, Beretta G, Piazza E, Luchena G, Aglione S, Bertolini A, Buzzoni R, Cabiddu M, Carnaghi C, Danova M, Farina G, Ferrari V, Frascaroli M, Reni M, Tansini G; AIOM Lombardia.

Tumori. 2013 Jan-Feb;99(1):45-50. doi: 10.1700/1248.13787.

PMID:
23548999
26.

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.

Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A.

Ann Oncol. 2013 Feb;24(2):406-411. doi: 10.1093/annonc/mds343. Epub 2019 Dec 4.

PMID:
32018414
27.

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.

Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A.

Ann Oncol. 2013 Feb;24(2):406-11. doi: 10.1093/annonc/mds343. Epub 2012 Oct 5.

28.

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A.

J Hepatol. 2012 Jul;57(1):101-7. doi: 10.1016/j.jhep.2012.02.016. Epub 2012 Mar 10.

PMID:
22414760
29.

Response assessment in oncology: limitations of anatomic response criteria in the era of tailored treatments.

Carnaghi C, Sclafani F, Basilico V, Doherty M.

Q J Nucl Med Mol Imaging. 2011 Dec;55(6):589-602. Review.

PMID:
22231580
30.

Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.

Sclafani F, Carnaghi C, Di Tommaso L, Rodari M, Destro A, Rimassa L, Giordano L, Chiti A, Roncalli M, Santoro A.

Tumori. 2011 Sep-Oct;97(5):620-8. doi: 10.1700/989.10722.

PMID:
22158494
31.

Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection.

Tronconi MC, Sclafani F, Rimassa L, Carnaghi C, Personeni N, Santoro A.

J Clin Oncol. 2011 Aug 10;29(23):e680-1. doi: 10.1200/JCO.2011.35.5651. Epub 2011 Jun 20. No abstract available.

32.

Is it time to reconsider the BCLC/AASLD therapeutic flow-chart?

Livraghi T, Brambilla G, Carnaghi C, Tommasini MA, Torzilli G.

J Surg Oncol. 2010 Dec 1;102(7):868-76. doi: 10.1002/jso.21733.

PMID:
20886553
33.

Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases.

Bignardi M, Navarria P, Mancosu P, Cozzi L, Fogliata A, Tozzi A, Castiglioni S, Carnaghi C, Tronconi MC, Santoro A, Scorsetti M.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):831-8. doi: 10.1016/j.ijrobp.2010.05.032. Epub 2010 Aug 26.

PMID:
20800375
34.

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.

Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi MC, Finocchiaro G, Rossoni G, Zanoni A, Miggiano C, Rizzardi GP, Traversari C, Caligaris-Cappio F, Lambiase A, Bordignon C.

Eur J Cancer. 2010 Oct;46(15):2746-52. doi: 10.1016/j.ejca.2010.07.012. Epub 2010 Aug 12.

PMID:
20708923
35.

Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancer.

Sclafani F, Carnaghi C, Colombo P, Bozzarelli S, De Vincenzo F, Rimassa L, Giorgetti PL, Santoro A.

Chemotherapy. 2010;56(3):203-7. doi: 10.1159/000316331. Epub 2010 Jun 11.

PMID:
20551636
36.

Rectal squamous cell carcinoma treated with chemoradiotherapy: report of six cases.

Tronconi MC, Carnaghi C, Bignardi M, Doci R, Rimassa L, Di Rocco M, Scorsetti M, Santoro A.

Int J Colorectal Dis. 2010 Dec;25(12):1435-9. doi: 10.1007/s00384-010-0988-4. Epub 2010 Jun 15.

PMID:
20549216
37.

A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.

Santoro A, Comandone A, Rimassa L, Granetti C, Lorusso V, Oliva C, Ronzoni M, Siena S, Zuradelli M, Mari E, Pressiani T, Carnaghi C.

Ann Oncol. 2008 Nov;19(11):1888-93. doi: 10.1093/annonc/mdn401. Epub 2008 Jul 30.

38.

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.

Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne PA.

Br J Cancer. 2008 Jul 8;99(1):83-9. doi: 10.1038/sj.bjc.6604439. Epub 2008 Jun 24.

39.

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.

Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M.

Ann Oncol. 2008 Apr;19(4):717-23. Epub 2007 Oct 31.

40.

Agreement between oncology guidelines and clinical practice in Italy: the 'right' program. A project of the Italian Association of Medical Oncology (AIOM).

Barni S, Venturini M, Beretta GD, Gori S, Molino A, Carnaghi C, Labianca R, Sgarbi S, Simoni L, Maiello E; AIOM Guidelines Task Force.

Ann Oncol. 2007 Jun;18 Suppl 6:vi179-84.

41.

Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy.

Carnaghi C, Tronconi MC, Rimassa L, Tondulli L, Zuradelli M, Rodari M, Doci R, Luttmann F, Torzilli G, Rubello D, Al-Nahhas A, Santoro A, Chiti A.

Nucl Med Rev Cent East Eur. 2007;10(1):12-5.

PMID:
17694495
42.

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.

Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S.

J Clin Oncol. 2007 Aug 1;25(22):3238-45.

PMID:
17664472
43.

Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer.

Malesci A, Laghi L, Bianchi P, Delconte G, Randolph A, Torri V, Carnaghi C, Doci R, Rosati R, Montorsi M, Roncalli M, Gennari L, Santoro A.

Clin Cancer Res. 2007 Jul 1;13(13):3831-9.

44.

The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study.

Carnaghi C, Santoro A, Rimassa L, Doci R, Rosati R, Pedicini V, Gullo G, Zuradelli M, Abbadessa G, Morenghi E, Marcon I, Garassino I.

Invest New Drugs. 2007 Oct;25(5):479-85. Epub 2007 May 11.

PMID:
17492399
45.

Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.

Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, Beretta GD, Catalano V, Bertetto O, Barni S, Frontini L, Aitini E, Rota S, Torri V, Floriani I; Italian Group for the Study of Digestive Tract Cancer, Pozzo C, Rimassa L, Mosconi S, Giordani P, Ardizzoia A, Foa P, Rabbi C, Chiara S, Gasparini G, Nardi M, Mansutti M, Arnoldi E, Piazza E, Cortesi E, Pucci F, Silva RR, Sobrero A, Ravaioli A.

J Natl Cancer Inst. 2007 Apr 18;99(8):601-7.

PMID:
17440161
46.

Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin.

Rimassa L, Gullo G, Carnaghi C, Abbadessa G, Zuradelli M, Tronconi MC, Pressiani T, Santoro A.

Tumori. 2006 Jul-Aug;92(4):285-9.

PMID:
17036517
47.

Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications.

Masci G, Magagnoli M, Pedicini V, Poretti D, Castagna L, Carnaghi C, Morenghi E, Del Vecchio A, Finotto R, Brambilla G, Santoro A.

Support Care Cancer. 2006 Nov;14(11):1141-6. Epub 2006 Apr 19.

PMID:
16622649
48.

Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.

Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L.

Endocr Relat Cancer. 2005 Sep;12(3):657-66.

PMID:
16172198
49.

High incidence of haemostatic interference in cancer patients treated with FOLFOX regimen and concomitant minidose of warfarin.

Magagnoli M, Masci G, Castagna L, Bramanti S, Morenghi E, Carnaghi C, Santoro A.

Br J Haematol. 2005 Jun;129(5):709-10. No abstract available.

PMID:
15916696
50.

Metastasis of hepatocellular carcinoma to the heart: a case report and review of the literature.

Masci G, Magagnoli M, Grimaldi A, Covini G, Carnaghi C, Rimassa L, Santoro A.

Tumori. 2004 May-Jun;90(3):345-7. Review.

PMID:
15315319

Supplemental Content

Loading ...
Support Center